πŸ‡ΊπŸ‡Έ FDA
Patent

US 11352607

Genomic engineering of pluripotent cells

granted A61KA61K2035/124A61K2239/31

Quick answer

US patent 11352607 (Genomic engineering of pluripotent cells) held by Fate Therapeutics, Inc. expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Fate Therapeutics, Inc.
Grant date
Tue Jun 07 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
28
CPC classes
A61K, A61K2035/124, A61K2239/31, A61K2239/38, A61K40/10